Nuclera agreed to collaborate with Cytiva to focus on accelerating the production, purification, and characterization of proteins needed for pharma R&D. The collaboration will work with Nuclera’s eProteinTM Discovery System with Cytiva’s Biacore
surface plasmon resonance (SPR) technology.
Proteins represent 95% of drug targets designed to combat disease, according to Yvonne Tan, PhD, associate director of product management at Nuclera, who explains that rapid access to these proteins and understanding how they interact with drug candidates is essential for drug development.
Typically, it takes months to obtain and characterize proteins, but she says that Nuclera and Cytiva together have achieved production and characterization within five days. Nuclera’s eProtein Discovery system was used to produce Bruton’s Tyrosine Kinase (BTK) and Vascular Endothelial Growth Factor (VEGF). These proteins were subsequently functionally characterized with Cytiva’s Biacore SPR system.
“Through this collaboration, we have demonstrated eProtein Discovery’s ability to produce clinically significant proteins that can be used in characterization experiments,” notes Tan.
“The ability of eProtein Discovery to accelerate protein production and purification complements Biacore SPR technology by streamlining the upstream protein production process,” adds Anna Moberg, senior manager and project manager, Cytiva.
The post Nuclera and Cytiva Collaborate on Protein Characterization for Drug Development appeared first on GEN - Genetic Engineering and Biotechnology News.
Proteins represent 95% of drug targets designed to combat disease, according to Yvonne Tan, PhD, associate director of product management at Nuclera, who explains that rapid access to these proteins and understanding how they interact with drug candidates is essential for drug development.
Typically, it takes months to obtain and characterize proteins, but she says that Nuclera and Cytiva together have achieved production and characterization within five days. Nuclera’s eProtein Discovery system was used to produce Bruton’s Tyrosine Kinase (BTK) and Vascular Endothelial Growth Factor (VEGF). These proteins were subsequently functionally characterized with Cytiva’s Biacore SPR system.
“Through this collaboration, we have demonstrated eProtein Discovery’s ability to produce clinically significant proteins that can be used in characterization experiments,” notes Tan.
“The ability of eProtein Discovery to accelerate protein production and purification complements Biacore SPR technology by streamlining the upstream protein production process,” adds Anna Moberg, senior manager and project manager, Cytiva.
The post Nuclera and Cytiva Collaborate on Protein Characterization for Drug Development appeared first on GEN - Genetic Engineering and Biotechnology News.